



Hillsborough, New Jersey, USA: 5th Oct, 2021.

ISHA Therapeutics LLC, announces successful completion of a pre-IND meeting with the US-FDA for its novel repurposed program called HANURA-001 – a nasal spray for the treatment of COVID19

ISHA Therapeutics LLC, a rising start-up company focused on advancing the science through repositioning/repurposing of the existing drugs with an aim to improve their safety and efficacy, today announced the successful completion of a formal pre-IND (Investigational New Drug) meeting for its **novel repurposed program called “HANURA-001 – a nasal spray for the treatment of COVID19”** with the Division of Pulmonology, Allergy, and Critical Care, Office of Immunology and Inflammation, Center for Drug Evaluation and Research, at the FDA.

The team discussed and sought critical inputs, guidance from the Agency on the proposed non-clinical, clinical and CMC product development plan for this ion-channel blocker molecule to be delivered via nasal route of administration for the treatment of COVID19.

A pre-IND meeting is a formal interaction between the Sponsor and the Agency to align and seek consensus on the IND development plan and obtain Agency’s guidance and recommendations on the planned clinical evaluation of proposed drug product. The FDA, after reviewing the submitted pre-clinical data, provided a written response to the specific questions and clarifications sought by the ISHA Therapeutic’s team on the clinical development plan (dose, dosing strategy, clinical study synopsis etc.), CMC for HANURA-001.

“We kindly appreciate the FDA’s guidance and recommendations to our program - HANURA-001, as we plan to propel the development of this therapeutic intervention for the treatment of COVID19 and contribute to this pandemic via developing an effective, affordable, accessible and patient compliant non-invasive therapeutic intervention for this deadly disease which has killed few million people across the world” said **Manoj Jadhav, PhD, FCP, Founder and CEO of ISHA Therapeutics LLC.**

About ISHA Therapeutics, LLC

ISHA Therapeutics is a rising start-up company focused on advancing the science through repositioning/repurposing of the existing drugs with an aim to improve their safety and efficacy and making these products accessible and available to the patients in the USA and globally. ISHA is working on several repurposed programs with an aim to fill in several unmet medical needs in the space of anti-infectives, dermatology, life style and chronic diseases. For more details visit www.Ishatherapeutics.com